Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GALR1 | P47211 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619481 | 0.83 | PTGER1 (0.59) | PTGER1NPC1GALR1 | |
| SCHEMBL4159104 | 0.83 | GRM7 (0.40) | PTGER1SMN1; SMN2NPC1 | |
| SCHEMBL6141435 | 0.81 | PTGER1 (0.52) | PTGER1NPC1GALR1 | |
| SCHEMBL4151518 | 0.79 | PTGER1 (0.61) | PTGER1SMN1; SMN2NPC1 | |
| SCHEMBL5620571 | 0.78 | PTGER1 (0.57) | PTGER1NPC1GALR1BRAF | |
| SCHEMBL4162371 | 0.77 | GALR1 (0.52) | SMN1; SMN2NPC1GALR1 | |
| SCHEMBL4162478 | 0.77 | PTGER1 (0.63) | PTGER1 | |
| SCHEMBL27796213 | 0.76 | NPC1 (0.46) | SMN1; SMN2NPC1GALR1BRAF | |
| SCHEMBL5619860 | 0.73 | PTGER1 (0.47) | PTGER1SMN1; SMN2BRAF | |
| SCHEMBL5620526 | 0.73 | PTGER1 (0.60) | PTGER1NPC1GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885SMN1; SMN2 3323/4885NPC1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.